BackAnuh Pharma Limited Overview

Anuh Pharma Limited EBIT

Latest ebit for ANUHPHR.BO: $620M, below the sector sector average of $2.4T.

Get informed when a big investor buys or sells

+ Follow

Quarterly EBIT

$151.00M
↑ 51.05% YoY

As of Sep 30, 2026

Annual EBIT (TTM)

$624.88M
↑ 20.12% YoY

Trailing 12 months ending Sep 30, 2026

Average EBIT (Comparison Companies)

EBIT History

EBIT Comparison

Annual EBIT Growth Rate (%)

Annual EBIT Growth (Absolute)

Anuh Pharma Limited (ANUHPHR.BO) FAQ

The latest EBIT for ANUHPHR.BO is $620M as of September 2026. That compares with $520M in the prior-year period — up 20.1% year over year. That is below the sector sector average of $2.4T. Investors often review this figure alongside Anuh Pharma Limited's historical trend and sector peers before judging valuation or financial health.

Over the past year, ANUHPHR.BO's EBIT moved from $520M to $620M — a 20.1% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Anuh Pharma Limited's operating scale or balance-sheet position.

Against its sector companies, ANUHPHR.BO currently prints $620M for EBIT, while the sector average sits near $2.4T. That is roughly 100.0% below the sector mean. Large gaps often invite a closer look at Anuh Pharma Limited's growth, margins, and balance sheet.

A EBIT figure of $620M for ANUHPHR.BO is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The sector average is about $2.4T. Explore the charts below for those layers of context.

After noting ANUHPHR.BO's EBIT ($620M), review year-over-year change from $520M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.